An untargeted multi-technique metabolomics approach to studying intracellular metabolites of HepG2 cells exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin

BMC Genomics

Volumn 12, Issue , 2011, Pages

  Ruiz Aracama, Ainhoa ^a,c   Peijnenburg, Ad ^a,c   Kleinjans, Jos ^b,c   Jennen, Danyel ^b,c   van Delft, Joost ^b,c   Hellfrisch, Caroline ^a   Lommen, Arjen ^a,c  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c Netherlands Toxicogenomics Centre   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; DIMETHYL SULFOXIDE;

ARTICLE; CELL METABOLISM; CONTROLLED STUDY; CYTOTOXICITY TEST; DATA ANALYSIS SOFTWARE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; INTRACELLULAR SPACE; LIVER TOXICITY; MASS FRAGMENTOGRAPHY; METABOLITE; METABOLOME; METABOLOMICS; NUCLEAR MAGNETIC RESONANCE; PROCESS DEVELOPMENT; UNTARGETED MULTI TECHNIQUE METABOLOMICS; VALIDATION PROCESS; CELL STRAIN HEPG2; CHEMISTRY; COMPUTER PROGRAM; DRUG EFFECT; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRINCIPAL COMPONENT ANALYSIS;

ANIMALIA;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIMETHYL SULFOXIDE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HEP G2 CELLS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; METABOLOME; METABOLOMICS; PRINCIPAL COMPONENT ANALYSIS; SOFTWARE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TETRACHLORODIBENZODIOXIN;

EID: 79956224108     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-12-251     Document Type: Article

References (83)

1. Nicholson JK, Lindon JC, Holmes E. Metabonomics: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999, 29:1181-1189. 10.1080/004982599238047, 10598751.
2. De Vos RCH, Moco S, Lommen A, Keurentjes JJB, Bino RJ, Hall RD. Untargeted large-scale plant metabolomics using liquid chromatography coupled to mass spectrometry. Nat Protoc 2007, 2:778-791. 10.1038/nprot.2007.95, 17446877.
3. Lommen A, van der Weg G, van Engelen MC, Bor G, Hoogenboom LAP, Nielen MWF. An untargeted metabolomics approach to contaminant analysis: Pinpointing potential unknown compounds. Anal Chim Acta 2007, 584:43-49. 10.1016/j.aca.2006.11.018, 17386583.
4. Fernie AR, Schauer N. Metabolomics-assisted breeding: a viable option for crop improvement?. Trends Genet 2008, 25:39-48.
5. Griffin JL. Understanding mouse models of disease through metabolomics. Curr Opin Chem Biol 2006, 10:309-315. 10.1016/j.cbpa.2006.06.027, 16815732.
6. Kaddurah-Daouk R, Kristal BS, Weinshilboum RM. Metabolomics: A Global Biochemical Approach to Drug Response and Disease. Annu Rev Pharmacol Toxicol 2008, 48:653-683. 10.1146/annurev.pharmtox.48.113006.094715, 18184107.
7. Powers R. NMR metabolomics and drug discovery. Magn Reson Chem 2009, 47:S2-S11. 10.1002/mrc.2461, 19504464.
8. Coen M, Holmes E, Lindon JC, Nicholson JK. NMR-Based Metabolic Profiling and Metabonomic Approaches to Problems in Molecular Toxicology. Chem Res Toxicol 2008, 21:9-27. 10.1021/tx700335d, 18171018.
9. Beger RD, Sun J, Schnackenberg LK. Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity. Toxicol Appl Pharmacol 243:154-166.
10. Ellis JK, Chan PH, Doktorova T, Athersuch TJ, Cavill R, Vanhaecke T, Rogiers V, Vinken M, Nicholson JK, Ebbels T MD, Keun HC. Effect of the Histone Deacetylase Inhibitor Trichostatin A on the Metabolome of Cultured Primary Hepatocytes. J Proteome Res 2009, 9:413-419.
11. van Vliet E, Morath S, Eskes C, Linge J, Rappsilber J, Honegger P, Hartung T, Coecke S. A novel in vitro metabolomics approach for neurotoxicity testing, proof of principle for methyl mercury chloride and caffeine. Neurotoxicology 2008, 29:1-12. 10.1016/j.neuro.2007.09.007, 18023877.
12. Vanhaecke T, Snykers S, Rogiers V, Garthoff B, Castell J, Hengstler J. EU research activities in alternative testing strategies: current status and future perspectives. Arch Toxicol 2009, 83:1037-1042. 10.1007/s00204-009-0484-1, 19908029.
13. Corvi R. Genomics: an in vitro toxicology point of view. Altern Lab Anim 2002, 30:129-131.
14. Snodin DJ. An EU perspective on the use of in vitro methods in regulatory pharmaceutical toxicology. Toxicol Lett 2002, 127:161-168. 10.1016/S0378-4274(01)00496-9, 12052654.
15. Jennen DGJ, Magkoufopoulou C, Ketelslegers HB, van Herwijnen MHM, Kleinjans JCS, van Delft JHM. Comparison of HepG2 and HepaRG by Whole-Genome Gene Expression Analysis for the Purpose of Chemical Hazard Identification. Toxicol Sci 2010, 115:66-79. 10.1093/toxsci/kfq026, 20106945.
16. van Delft JHM, van Agen E, van Breda SGJ, Herwijnen MH, Staal YCM, Kleinjans JCS. Discrimination of genotoxic from non-genotoxic carcinogens by gene expression profiling. Carcinogenesis 2004, 25:1265-1276. 10.1093/carcin/bgh108, 14963013.
17. van Delft JHM, van Agen E, van Breda SGJ, Herwijnen MH, Staal YCM, Kleinjans JCS. Comparison of supervised clustering methods to discriminate genotoxic from non-genotoxic carcinogens by gene expression profiling. Mutat Res, Fundam Mol Mech Mutagen 2005, 575:17-33.
18. Winkler J, Sotiriadou I, Chen S, Hescheler J, Sachinidis A. The Potential of Embryonic Stem Cells Combined with -omics Technologies as Model Systems for Toxicology. Curr Med Chem 2009, 16:4814-4827. 10.2174/092986709789909657, 19929785.
19. Landers JP, Bunce NJ. The Ah receptor and the mechanism of dioxin toxicity. Biochem J 1991, 276:273-287. 1151088, 1646595.
20. Mandal PK. Dioxin: a review of its environmental effects and its aryl hydrocarbon receptor biology. J Comp Physiol, B 2005, 175:221-230.
21. Uno S, Dalton TP, Sinclair PR, Gorman N, Wang B, Smith AG, Miller ML, Shertzer HG, Nebert DW. Cyp1a1(-/-) male mice: protection against high-dose TCDD-induced lethality and wasting syndrome, and resistance to intrahepatocyte lipid accumulation and uroporphyria. Toxicol Appl Pharmacol 2004, 196:410-421. 10.1016/j.taap.2004.01.014, 15094312.
22. Senft AP, Dalton TP, Nebert DW, Genter MB, Hutchinson RJ, Shertzer HG. Dioxin Increases Reactive Oxygen Production in Mouse Liver Mitochondria. Toxicol Appl Pharmacol 2002, 178:15-21. 10.1006/taap.2001.9314, 11781075.
23. Shertzer HG, Nebert DW, Puga A, Ary M, Sonntag D, Dixon K, Robinson LJ, Cianciolo E, Dalton TP. Dioxin Causes a Sustained Oxidative Stress Response in the Mouse. Biochem Biophys Res Commun 1998, 253:44-48. 10.1006/bbrc.1998.9753, 9875217.
24. Poland A, Knutson JC. 2,3,7,8-Tetrachlorodibenzo-p-Dioxin and Related Halogenated Aromatic Hydrocarbons: Examination of the Mechanism of Toxicity. Annu Rev Pharmacol Toxicol 1982, 22:517-554. 10.1146/annurev.pa.22.040182.002505, 6282188.
25. Safe S. Molecular biology of the Ah receptor and its role in carcinogenesis. Toxicol Lett 2001, 120:1-7. 10.1016/S0378-4274(01)00301-0, 11323156.
26. Puga A, Maier A, Medvedovic M. The transcriptional signature of dioxin in human hepatoma HepG2 cells. Biochem Pharmacol 2000, 60:1129-1142. 10.1016/S0006-2952(00)00403-2, 11007951.
27. Hankinson O. The Aryl Hydrocarbon Receptor Complex. Annu Rev Pharmacol Toxicol 1995, 35:307-340. 10.1146/annurev.pa.35.040195.001515, 7598497.
28. Knasmüller S, Parzefall W, Sanyal R, Ecker S, Schwab C, Uhl M, Mersch-Sundermann V, Williamson G, Hietsch G, Langer T, Darroudi F, Natajaran AT. Use of metabolically competent human hepatoma cells for the detection of mutagens and antimutagens. Mutat Res, Fundam Mol Mech Mutagen 1998, 402:185-202.
29. Hockley SL, Mathijs K, Staal YCM, Brewer D, Giddings I, van Delft JHM, Phillips DH. Interlaboratory and Interplatform Comparison of Microarray Gene Expression Analysis of HepG2 Cells Exposed to Benzo(a)pyrene. OMICS 2009, 13:115-125. 10.1089/omi.2008.0060, 19245359.
30. Wilkening S, Stahl F, Bader A. Comparison of primary human hepatocytes and hepatoma cell line HepG2 with regard with their biotransformation properties. Drug Metab Dispos 2003, 31:1035-1042. 10.1124/dmd.31.8.1035, 12867492.
31. Lommen A. MetAlign: Interface-Driven, Versatile Metabolomics Tool for Hyphenated Full-Scan Mass Spectrometry Data Preprocessing. Anal Chem 2009, 81:3079-3086. 10.1021/ac900036d, 19301908.
32. Lommen A, Weseman JM, Smith GO, Noteborn HPJM. On the detection of environmental effects on complex matrices combining off-line liquid chromatography and 1H-NMR. Biodegradation 1998, 9:513-525.
33. Noteborn HPJM, Lommen A, van der Jagt RC, Weseman JM. Chemical fingerprinting for the evaluation of unintended secondary metabolic changes in transgenic food crops. J Biotechnol 2000, 77:103-114. 10.1016/S0168-1656(99)00210-2, 10674217.
34. MetAlign. , http://www.metalign.nl
35. Kinehara M, Fukuda I, Yoshida K, Ashida H. Aryl hydrocarbon receptor-mediated induction of the cytosolic phospholipase A(2)alpha gene by 2,3,7,8-tetrachlorodibenzo-p-dioxin in mouse hepatoma Hepa-1c1c7 cells. J Biosci Bioeng 2009, 108:277-281. 10.1016/j.jbiosc.2009.04.015, 19716514.
36. Dayoub R, Thasler WE, Bosserhoff AK, Singer T, Jauch KW, Schlitt HJ, Weiss TS. Regulation of polyamine synthesis in human hepatocytes by hepatotrophic factor augmenter of liver regeneration. Biochem Biophys Res Commun 2006, 345:181-187. 10.1016/j.bbrc.2006.04.040, 16677602.
37. Raasch W, Regunathan S, Li G, Reis DJ. Agmatine, the bacterial amine, is widely distributed in mammalian tissues. Life Sci 1995, 56:2319-2330. 10.1016/0024-3205(95)00226-V, 7791519.
38. Potter CL, Sipes IG, Russell DH. Inhibition of ornithine decarboxylase activity by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Biochem Pharmacol 1982, 3:3367-3371.
39. Thomas T, MacKenzie SA, Gallo MA. Regulation of polyamine biosynthesis by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Toxicol Lett 1990, 53:315-325. 10.1016/0378-4274(90)90236-F, 2237938.
40. Pegg AE, McCann PP. Polyamine metabolism and function. Am J Physiol. Cell Physiol 1982, 243:C212-221.
41. Boverhof DR, Burgoon LD, Tashiro C, Sharratt B, Chittim B, Harkema JR, Mendrick DL, Zacharewski TR. Comparative Toxicogenomic Analysis of the Hepatotoxic Effects of TCDD in Sprague Dawley Rats and C57BL/6 Mice. Toxicol Sci 2006, 94:398-416. 10.1093/toxsci/kfl100, 16960034.
42. Fletcher N, Wahlström D, Lundberg R, Nilsson CB, Nilsson KC, Stockling K, Hellmold H, Håkansson H. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) alters the mRNA expression of critical genes associated with cholesterol metabolism, bile acid biosynthesis, and bile transport in rat liver: A microarray study. Toxicol Appl Pharmacol 2005, 207:1-24.
43. Seefeld MD, Corbett SW, Keesey RE, Peterson RE. Characterization of the wasting syndrome in rats treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Appl Pharmacol 1984, 73:311-322. 10.1016/0041-008X(84)90337-5, 6710531.
44. Lakshman MR, Campbell BS, Chirtel SJ, Ekarohita N. Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on de novo fatty acid and cholesterol synthesis in the rat. Lipids 1988, 23:904-906. 10.1007/BF02536213, 3185127.
45. Lakshman MR, Chirtel SJ, Chambers LL, Coutlakis PJ. Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on lipid synthesis and lipogenic enzymes in the rat. J Pharmacol Exp Ther 1989, 248:62-66.
46. McKim J, Marien K, Schaup H, Selivonchick D. Alterations of hepatic acetyl-CoA carboxylase by 2,3,7,8-tetrachlorodibenzo- p -dioxin. Lipids 1991, 26:521-525. 10.1007/BF02536597, 1682781.
47. Boverhof DR, Burgoon LD, Tashiro C, Chittim B, Harkema JR, Jump DB, Zacharewski TR. Temporal and Dose-Dependent Hepatic Gene Expression Patterns in Mice Provide New Insights into TCDD-Mediated Hepatotoxicity. Toxicol Sci 2005, 85:1048-1063. 10.1093/toxsci/kfi162, 15800033.
48. Nishiumi S, Yabushita Y, Furuyashiki T, Fukuda I, Ashida H. Involvement of SREBPs in 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced disruption of lipid metabolism in male guinea pig. Toxicol Appl Pharmacol 2008, 229:281-289. 10.1016/j.taap.2008.01.030, 18336851.
49. Sato S, Shirakawa H, Tomita S, Ohsaki Y, Haketa K, Tooi O, Santo N, Tohkin M, Furukawa Y, Gonzalez FJ, Komai M. Low-dose dioxins alter gene expression related to cholesterol biosynthesis, lipogenesis, and glucose metabolism through the aryl hydrocarbon receptor-mediated pathway in mouse liver. Toxicol Appl Pharmacol 2008, 229:10-19. 10.1016/j.taap.2007.12.029, 18295293.
50. Alexander DL, Ganem LG, Fernandez-Salguero P, Gonzalez F, Jefcoate CR. Aryl-hydrocarbon receptor is an inhibitory regulator of lipid synthesis and of commitment to adipogenesis. J Cell Sci 1998, 111:3311-3322.
51. Vogel CFA, Matsumura F. Interaction of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) with induced adipocyte differentiation in mouse embryonic fibroblasts (MEFs) involves tyrosine kinase c-Src. Biochem Pharmacol 2003, 66:1231-1244. 10.1016/S0006-2952(03)00404-0, 14505802.
52. Ntambi JM, Miyazaki M, Stoehr JP, Lan H, Kendziorski CM, Yandell BS, Song Y, Cohen P, Friedman JM, Attie AD. Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proc Natl Acad Sci USA 2002, 99:11482-11486. 10.1073/pnas.132384699, 123282, 12177411.
53. Sewell AC, Böhles HJ. Acylcarnitines in intermediary metabolism. Eur J Pediatr 1995, 154:871-877. 10.1007/BF01957495, 8582396.
54. Siliprandi N, Lisa F, Menabò R. Propionyl-L-carnitine: Biochemical significance and possible role in cardiac metabolism. Cardiovasc Drugs Ther 1991, 5:11-15. 10.1007/BF00128238, 2031869.
55. Schiller CM, Adcock CM, Moore RA, Walden R. Effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and fasting on body weight and lipid parameters in rats. Toxicol Appl Pharmacol 1985, 81:356-361. 10.1016/0041-008X(85)90173-5, 4060161.
56. Swift LL, Gasiewicz TA, Dunn GD, Soulé PD, Neal RA. Characterization of the hyperlipidemia in guinea pigs induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Appl Pharmacol 1981, 59:489-499. 10.1016/0041-008X(81)90302-1, 7268772.
57. Viluksela M, Unkila M, Pohjanvirta R, Tuomisto JT, Stahl BU, Rozman KK, Tuomisto J. Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on liver phosphoenolpyruvate carboxykinase (PEPCK) activity, glucose homeostasis and plasma amino acid concentrations in the most TCDD-susceptible and the most TCDD-resistant rat strains. Arch Toxicol 1999, 73:323-336. 10.1007/s002040050626, 10447560.
58. Albro PW, Corbett JT, Harris M, Lawson LD. Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on lipid profiles in tissue of the Fischer rat. Chem Biol Interact 1978, 23:315-330. 10.1016/0009-2797(78)90093-5, 719812.
59. Hassan MQ, Stohs SJ, Murray WJ. Comparative ability of TCDD to induce lipid peroxidation in rats, guinea pigs, and Syrian golden hamsters. Bull Environ Contam Toxicol 1983, 31:649-657. 10.1007/BF01606041, 6661579.
60. Pohjanvirta R, Sankari S, Kulju T, Naukkarinen A, Ylinen M, Tuomisto J. Studies on the Role of Lipid Peroxidation in the Acute Toxicity of TCDD in Rats. Pharmacol Toxicol 1990, 66:399-408. 10.1111/j.1600-0773.1990.tb00769.x, 2371248.
61. Hilscherova K, Blankenship AL, Nie M, Coady KK, Upham BL, Trosko JE, Giesy JP. Oxidative stress in liver and brain of the hatchling chicken (Gallus domesticus) following in ovo injection with TCDD. Comp Biochem Physiol C Toxicol Pharmacol 2003, 136:29-45. 10.1016/S1532-0456(03)00167-4, 14522597.
62. Deneke SM, Fanburg BL. Regulation of cellular glutathione. Am J Physiol Lung Cell Mol Physiol 1989, 257:L163-173.
63. Reed DJ. Glutathione: Toxicological Implications. Annu Rev Pharmacol Toxicol 1990, 30:603-631. 10.1146/annurev.pa.30.040190.003131, 2188580.
64. Aly HAA, Domènech T. Cytotoxicity and mitochondrial dysfunction of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in isolated rat hepatocytes. Toxicol Lett 2009, 191:79-87. 10.1016/j.toxlet.2009.08.008, 19686823.
65. Kern PA, Fishman RB, Song W, Brown AD, Fonseca V. The effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on oxidative enzymes in adipocytes and liver. Toxicology 2002, 171:117-125. 10.1016/S0300-483X(01)00564-9, 11836018.
66. Hassan MQ, Stohs SJ, Murray WJ. Inhibition of TCDD-induced lipid peroxidation, glutathione peroxidase activity and toxicity by BHA and glutathione. Bull Environ Contam Toxicol 1985, 34:787-796. 10.1007/BF01609808, 4016287.
67. Schmidt A, Marescau B, Boehm EA, Renema WKJ, Peco R, Das A, Steinfeld R, Chan S, Wallis J, Davidoff M, Ullrich K, Waldschütz R, Heerschap A, De Deyn PP, Neubauer S, Isbrandt D. Severely altered guanidino compound levels, disturbed body weight homeostasis and impaired fertility in a mouse model of guanidinoacetate N-methyltransferase (GAMT) deficiency. Hum Mol Gen 2004, 13:905-921. 10.1093/hmg/ddh112, 15028668.
68. Huxtable RJ. Physiological actions of taurine. Physiol Rev 1992, 72:101-163.
69. Park T, Oh J, Lee K. Dietary taurine or glycine supplementation reduces plasma and liver cholesterol and triglyceride concentrations in rats fed a cholesterol-free diet. Nutr Res 1999, 19:1777-1789.
70. Yanagita T, Han SY, Hu Y, Nagao K, Kitajima H, Murakami S. Taurine reduces the secretion of apolipoprotein B100 and lipids in HepG2 cells. Lipids Health Dis 2008, 7:38. 10.1186/1476-511X-7-38, 2579289, 18925970.
71. Cimafranca MA, Hanlon PR, Jefcoate CR. TCDD administration after the pro-adipogenic differentiation stimulus inhibits PPARγ through a MEK-dependent process but less effectively suppresses adipogenesis. Toxicol Appl Pharmacol 2004, 196:156-168. 10.1016/j.taap.2003.12.005, 15050417.
72. Hanlon PR, Zheng W, Ko AY, Jefcoate CR. Identification of novel TCDD-regulated genes by microarray analysis. Toxicol Appl Pharmacol 2005, 202:215-228. 10.1016/j.taap.2004.06.018, 15667827.
73. Konrad RJ, Kudlow JE. The role of O-linked protein glycosylation in beta-cell dysfunction. Int J Mol Med 2002, 10:535-539.
74. Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, Lee D, von Goetz M, Yee SF, Totpal K, Huw L, Katta V, Cavet G, Hymowitz SG, Amler L, Ashkenazi A. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 2007, 13:1070-1077. 10.1038/nm1627, 17767167.
75. Kim S, Dere E, Burgoon LD, Chang CC, Zacharewski TR. Comparative Analysis of AhR-Mediated TCDD-Elicited Gene Expression in Human Liver Adult Stem Cells. Toxicol Sci 2009, 112:229-244. 10.1093/toxsci/kfp189, 2769060, 19684285.
76. Kim JH, In YJ, Kim WK, Bae KH, Kang S, Lee SC. Differential signatures of protein glycosylation and phosphorylation in human Chang liver cells induced by TCDD treatment. Toxicol Lett 2008, 178:20-28. 10.1016/j.toxlet.2008.01.019, 18358643.
77. Baslow MH. N-Acetylaspartate in the Vertebrate Brain: Metabolism and Function. Neurochem Res 2003, 28:1573-6903.
78. Rubin Y, Connelly GP, Lenkinski RE. N-acetylaspartate complexes with calcium and lanthanide ions. J Inorg Biochem 1995, 60:31-43. 10.1016/0162-0134(94)00132-T, 7595470.
79. GeneMaths. , http://www.applied-maths.com/genemaths/genemaths.htm
80. The Human Metabolome Database. , http://www.hmdb.ca/
81. Oostendorp M, Engelke UFH, Willemsen MAAP, Wevers RA. Diagnosing Inborn Errors of Lipid Metabolism with Proton Nuclear Magnetic Resonance Spectroscopy. Clin Chem 2006, 52:1395-1405. 10.1373/clinchem.2006.069112, 16709621.
82. Fan TWM, Lane AN. Structure-based profiling of metabolites and isotopomers by NMR. Prog Nucl Magn Reson Spectrosc 2008, 52:69-117.
83. Govindaraju V, Young K, Maudsley AA. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed 2000, 13:129-153. 10.1002/1099-1492(200005)13:3<129::AID-NBM619>3.0.CO;2-V, 10861994.